Jasdave Chahal
Fundador en Tiba Biotech LLC .
Perfil
Jasdave Chahal is a Chief Scientist and founder of Tiba Biotech LLC, which is founded in 2018.
He is currently a Venture Partner at incTANK Inc. Mr. Chahal received his undergraduate degree from the University of Ottawa in 2006 and his doctorate from Princeton University in 2012.
Cargos activos de Jasdave Chahal
Empresas | Cargo | Inicio |
---|---|---|
Tiba Biotech LLC
Tiba Biotech LLC BiotechnologyHealth Technology Tiba Biotech LLC is a company that specializes in advancing the RNA medicine field with an improved approach to nucleic acid delivery. The company is based in Cambridge, MA. The company has developed a fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics, as well as a computational RNA design for more potent gene expression. The company's goal is to achieve better patient outcomes through rational design, from gene to delivery method beyond vaccines. The company was founded in 2017 by Christian Mandl, Karl H. Ruping, Jasdave Chahal. Karl H. Ruping has been the CEO since 2017. | Fundador | 01/01/2018 |
incTANK Inc
incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Inversor de Capital Privado | - |
Formación de Jasdave Chahal.
University of Ottawa | Undergraduate Degree |
Princeton University | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
incTANK Inc
incTANK Inc Investment ManagersFinance incTANK Inc (incTANK) is a venture capital firm founded in 1999 by Karl H. Ruping. The firm is headquartered in the Cambridge, Massachusetts. | Finance |
Tiba Biotech LLC
Tiba Biotech LLC BiotechnologyHealth Technology Tiba Biotech LLC is a company that specializes in advancing the RNA medicine field with an improved approach to nucleic acid delivery. The company is based in Cambridge, MA. The company has developed a fully biodegradable nanoparticle delivery platform for safer vaccines and therapeutics, as well as a computational RNA design for more potent gene expression. The company's goal is to achieve better patient outcomes through rational design, from gene to delivery method beyond vaccines. The company was founded in 2017 by Christian Mandl, Karl H. Ruping, Jasdave Chahal. Karl H. Ruping has been the CEO since 2017. | Health Technology |
- Bolsa de valores
- Insiders
- Jasdave Chahal